Cargando…

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia that may appear as de-novo leukemia (pPCL) or on the basis of a pre-existing multiple myeloma (MM), called secondary plasma cell leukemia (sPCL). In this prospective study, we have applied a broad panel of FISH probes in 965 n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papadhimitriou, Stefanos I., Terpos, Evangelos, Liapis, Konstantinos, Pavlidis, Dimitrios, Marinakis, Theodoros, Kastritis, Efstathios, Dimopoulos, Meletios-Athanasios, Tsitsilonis, Ourania E., Kostopoulos, Ioannis V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869452/ https://www.ncbi.nlm.nih.gov/pubmed/35203419 http://dx.doi.org/10.3390/biomedicines10020209

Ejemplares similares

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis
por: Kostopoulos, I V, et al.
Publicado: (2017)

Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
por: Orologas-Stavrou, Nikolaos, et al.
Publicado: (2020)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2018)

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals
por: Mavragani, Clio P., et al.
Publicado: (2022)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response
por: Dagla, Ioanna, et al.
Publicado: (2022)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

Familial chronic lymphocytic leukemia in two siblings with ATM/13q14 deletion and a similar pattern of clonal evolution
por: Kostopoulos, I V, et al.
Publicado: (2015)

P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
por: Malandrakis, Panagiotis, et al.
Publicado: (2023)

The Emerging Role of Convalescent Plasma in the Treatment of COVID-19
por: Psaltopoulou, Theodora, et al.
Publicado: (2020)

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
por: Bagratuni, Tina, et al.
Publicado: (2020)

Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker
por: Birmpilis, Anastasios I., et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells
por: Skorda, Aikaterini, et al.
Publicado: (2019)

Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study
por: Kalapanida, Despoina, et al.
Publicado: (2018)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
por: Fotiou, Despina, et al.
Publicado: (2020)

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
por: Terpos, Evangelos, et al.
Publicado: (2019)

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2018)

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
por: Melea, Pelagia I., et al.
Publicado: (2014)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

The extended 4-year follow-up results of the ELOQUENT-2 trial
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses
por: Georgakopoulou, Rebecca, et al.
Publicado: (2021)

Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit
por: Liontos, Michalis, et al.
Publicado: (2021)

Monoclonal Gammopathy of Thrombotic Significance
por: Gkalea, Vasiliki, et al.
Publicado: (2023)

Organ-specific manifestations of COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
por: Trougakos, Ioannis P., et al.
Publicado: (2022)

COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns
por: Trougakos, Ioannis P., et al.
Publicado: (2022)

Etiopathogenetic Mechanisms in Diverticular Disease of the Colon
por: Camilleri, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_95h9gcsk56n75n6svmapo5v65p